Jane Street’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $230K | Sell |
15,900
-11,300
| -42% | -$162K | ﹤0.01% | 9824 |
|
|
2025
Q4 | $387K | Buy |
27,200
+7,700
| +39% | +$75.6K | ﹤0.01% | 8265 |
|
|
2025
Q3 | $154K | Buy |
+19,500
| New | +$139K | ﹤0.01% | 9869 |
|
|
2024
Q1 | – | Sell |
-53,500
| Closed | -$759K | – | 9474 |
|
|
2023
Q4 | $759K | Buy |
53,500
+4,000
| +8% | +$45.4K | ﹤0.01% | 6065 |
|
|
2023
Q3 | $602K | Buy |
49,500
+20,200
| +69% | +$261K | ﹤0.01% | 5997 |
|
|
2023
Q2 | $368K | Buy |
+29,300
| New | +$348K | ﹤0.01% | 6809 |
|
|
2023
Q1 | – | Sell |
-31,900
| Closed | -$389K | – | 9295 |
|
|
2022
Q4 | $389K | Sell |
31,900
-115,900
| -78% | -$1.3M | ﹤0.01% | 6580 |
|
|
2022
Q3 | $1.54M | Buy |
147,800
+6,300
| +4% | +$70.2K | ﹤0.01% | 4630 |
|
|
2022
Q2 | $1.52M | Buy |
141,500
+88,800
| +169% | +$731K | ﹤0.01% | 4681 |
|
|
2022
Q1 | $499K | Buy |
52,700
+21,700
| +70% | +$203K | ﹤0.01% | 7486 |
|
|
2021
Q4 | $358K | Sell |
31,000
-2,400
| -7% | -$26.7K | ﹤0.01% | 7852 |
|
|
2021
Q3 | $319K | Sell |
33,400
-24,500
| -42% | -$251K | ﹤0.01% | 8061 |
|
|
2021
Q2 | $558K | Sell |
57,900
-117,100
| -67% | -$1.14M | ﹤0.01% | 7033 |
|
|
2021
Q1 | $1.73M | Buy |
175,000
+111,800
| +177% | +$1.73M | ﹤0.01% | 4310 |
|
|
2020
Q4 | $1.46M | Sell |
63,200
-81,300
| -56% | -$1.66M | ﹤0.01% | 4048 |
|
|
2020
Q3 | $2.04M | Sell |
144,500
-57,200
| -28% | -$834K | ﹤0.01% | 3002 |
|
|
2020
Q2 | $3.04M | Buy |
+201,700
| New | +$2.46M | ﹤0.01% | 2486 |
|
|
2018
Q4 | – | Sell |
-23,100
| Closed | -$279K | – | 5185 |
|
|
2018
Q3 | $279K | Buy |
23,100
+10,900
| +89% | +$152K | ﹤0.01% | 4302 |
|
|
2018
Q2 | $191K | Buy |
+12,200
| New | +$184K | ﹤0.01% | 4583 |
|
|
2018
Q1 | – | Sell |
-15,300
| Closed | -$220K | – | 4971 |
|
|
2017
Q4 | $220K | Sell |
15,300
-300
| -2% | -$4.12K | ﹤0.01% | 4104 |
|
|
2017
Q3 | $235K | Buy |
+15,600
| New | +$206K | ﹤0.01% | 3967 |
|
|
2017
Q1 | – | Sell |
-11,400
| Closed | -$57K | – | 4310 |
|
|
2016
Q4 | $57K | Buy |
+11,400
| New | +$78.9K | ﹤0.01% | 3925 |
|
|
2016
Q2 | – | Sell |
-103,200
| Closed | -$872K | – | 4225 |
|
|
2016
Q1 | $872K | Buy |
+103,200
| New | +$731K | ﹤0.01% | 1980 |
|
|
2015
Q4 | – | Sell |
-14,000
| Closed | -$196K | – | 4133 |
|
|
2015
Q3 | $196K | Sell |
14,000
-25,800
| -65% | -$405K | ﹤0.01% | 3199 |
|
|
2015
Q2 | $563K | Buy |
+39,800
| New | +$478K | ﹤0.01% | 2161 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Jane Street's FOLD Position: Q1 2026 in Review
Jane Street reduced its Amicus Therapeutics (FOLD) stake by 59% in Q1 2026, selling an estimated $6.14M and leaving 298,632 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3719.
Jane Street first reported a position in FOLD in Q3 2013 and has held it in 44 quarters since. The position peaked at $10.3M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Jane Street held 298,632 shares of Amicus Therapeutics worth $4.32M as of Q1 2026.
- Jane Street sold 428,165 Amicus Therapeutics shares in Q1 2026, an estimated $6.14M.
- Amicus Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3719 holding.
- Jane Street first reported a position in Amicus Therapeutics in Q3 2013 and has held it in 44 quarters since.
- Jane Street's Amicus Therapeutics position peaked at $10.3M in Q4 2025.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.